DEXTROSE 7.7% IN PLASTIC CONTAINER Drug Patent Profile

« Back to Dashboard

Which patents cover Dextrose 7.7% In Plastic Container, and what generic alternatives are available?

Dextrose 7.7% In Plastic Container is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in DEXTROSE 7.7% IN PLASTIC CONTAINER is dextrose. Sixteen suppliers are listed for this compound. Additional details are available on the dextrose profile page.

Summary for DEXTROSE 7.7% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DEXTROSE 7.7% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	DEXTROSE 7.7% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	019626-003	Feb 2, 1988		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Dextrose 7.7% in Plastic Container (IV Infusion)

Last updated: July 16, 2026

Dextrose 7.7% in a plastic IV container is a generic, commodity-style sterile infusion used for IV dextrose delivery. The patent and exclusivity landscape is typically limited, and the commercial risk is dominated by manufacturing scale, sourcing of pharmaceutical-grade dextrose, container/closure qualification, sterility assurance, and pricing pressure from multi-source wholesalers and GPO contracting rather than brand-level IP scarcity.

What is dextrose 7.7% in plastic container and how is it used clinically?

Dextrose 7.7% IV solution is an isotonic-to-hypertonic glucose infusion product used for glucose provision, maintenance fluids, and selected inpatient nutrition or hydration regimens where dextrose is indicated. It is supplied as a sterile IV infusion in flexible plastic containers (typically PVC-free formulations or specific container systems depending on manufacturer) intended for gravity or pump-assisted administration.

Key clinical drivers

• Inpatient fluid management where glucose is required
• Perioperative and critical care settings for controlled glucose administration
• Step-down use for patients transitioning between higher and lower concentration dextrose solutions

Dose, route, and product attributes investors track

• Route: IV infusion
• Concentration: 7.7% dextrose (w/v)
• Presentation: plastic container; often in specific bag sizes (varies by label)
• Sterility and container integrity: critical for supply continuity and recalls

What matters for formularies and purchasing

• Acquisition cost and net pricing after rebates/discounts
• Ability to meet distribution schedules and institution contracts
• Container format preference driven by nursing workflow and compatibility

How does the Orange Book status of dextrose 7.7% products affect investment risk?

For generic IV solutions like dextrose 7.7%, Orange Book coverage is usually not a meaningful moat. Many dextrose infusion products are “unbranded generics” or legacy products with limited, if any, enforceable small-molecule formulation patents that would block competitors beyond standard market entry timelines. In most cases, the key exclusion risk is not patent-expiration uncertainty but short-cycle manufacturer qualification and regulatory/CMC barriers.

What to expect from typical Orange Book patterns

• Potential listings for patents related to manufacturing, formulation, or container stability may exist, but:
  • They are often narrow in scope
  • They are rarely the primary determinant of market entry for commodity IV solutions
• New entrants are usually constrained by:
  • FDA approval status and inspection outcomes
  • CMC comparability and stability data
  • Container system qualification and lot-release testing capability

Bottom-line implication

The investment case usually depends more on scale economics and operational resilience than on exclusivity-driven revenue visibility.

What patents protect dextrose 7.7% in plastic container, and how strong is the patent estate?

For dextrose IV solutions, patent estates are typically fragmented across:

• Sterile manufacturing processes
• Container formulations and stability claims
• Methods for preparing the solution and ensuring stability

In practice, competitive entry is most often a manufacturing and regulatory competition. Where patents exist, they tend to be less robust than for novel therapeutics, and they may not prevent generic-style supply.

Where investors should focus instead of “blockbuster IP”

• CMC defensibility: validated sterilization, filtration/sterility assurance, and container compatibility testing
• Regulatory defensibility: successful FDA inspections and batch release performance
• Supply continuity: backup sites, redundant QA release, and container supplier resilience
• Quality outcomes: deviation rate, OOS/OOT frequency, complaint rates

When does dextrose 7.7% lose exclusivity, and what drives entry timing?

Exclusivity in commodity IV solutions is usually governed by:

• Initial FDA approval or supplemental changes for specific NDA/ANDA holders
• 180-day exclusivity for first generics is possible but less common for this kind of product category
• Patent term expiration for any listed patents that could delay generic competition

What drives the practical “clock”

• ANDA approval timelines and “work-sharing” or facility readiness
• Time to qualify container systems, fill-finish lines, and stability protocol acceptance
• Inspection schedules and batch release backlogs

Featured snippet answer

Exclusivity is rarely the investment driver; market entry timing is driven by FDA/CMC readiness and supply chain qualification rather than enforceable long-duration patent barriers.

What generic entry risks exist for dextrose 7.7% in plastic container?

Generic entry risk is high because:

• The active ingredient is widely sourced
• Formulation is simple and well-known at a pharmacopoeial level
• Competitive products are frequently interchangeable at the product category level (with some constraints around container format and bag sizes)

Specific entry vectors investors should model

• New ANDA or “therapeutic equivalence” supply expansions by major sterile injectables players
• Contract manufacturing and private-label expansion by sterile solution specialists
• Substitution at institutional formularies when net price drops

Net impact

Price compression is the core threat. IP-driven risk is usually secondary unless a holder has an unusually strong container/manufacturing patent block or regulatory exclusivity tied to a specific change.

How does dextrose 7.7% compare with other dextrose IV concentrations for revenue exposure?

Revenue exposure is often concentration mix-dependent:

• Higher concentrations (if supply-constrained) can price better but have different clinical use profiles
• Lower or standard concentrations often face more commoditization and more multi-source competition
• Bag size and container system can affect tender outcomes

Investment relevance

A holder with a broader dextrose ladder (multiple concentrations) can smooth procurement risk. A single-concentration dependency can expose revenue to rapid price changes from competitive tender cycles.

What FDA regulatory pathway applies, and what CMC barriers control approvals?

Dextrose IV solutions are typically supported through ANDAs for generic equivalents or through NDA holders for specific presentations. The investment barrier is CMC execution and sterile manufacturing control.

CMC elements that gate approvals

• Sterility assurance and validation package completeness
• Filter/sterilization compatibility with container-bag extractables profile
• Stability data for labeled shelf life under storage conditions
• Container closure integrity testing and extractables/leachables data as required by the application type

Inspection and batch release as economic variables

• FDA inspection results determine whether supply ramps
• Batch release reliability determines distribution continuity and can directly affect contract retention

Which companies are likely to compete for supply, and how do procurement dynamics work?

Competition typically involves:

• Large sterile injectables manufacturers with scale filling capacity
• Portfolio players supplying hospital and distributor channels
• Wholesalers and GPO-influenced distribution networks

Procurement mechanics that matter

• Tender cycles at hospital systems
• Contract pricing indexed to acquisition cost plus distribution margins
• Formulary substitution based on therapeutic equivalence and delivery reliability

Investment takeaway

The “winner” is usually the lowest-cost reliable supplier with qualified manufacturing sites, not the best IP holder.

How strong is the business moat for dextrose 7.7% solutions?

For this category, moat strength is mostly operational.

Moat categories

1. Cost moat

   • Bulk dextrose sourcing
   • Yield and batch productivity in sterile fill-finish
   • Lower QA release and deviation costs through process control

2. Supply moat

   • Multiple manufacturing lines
   • Multiple container suppliers
   • Redundant sterilization/filtration validation readiness

3. Quality moat

   • Low complaint rates and high batch acceptance
   • Strong CAPA systems that reduce recurrence

What does not usually create a moat

• Strong, enforceable patents over a broad product claim set
• Brand-level prescribing loyalty (rare for commodity IV solutions)

What manufacturing and supply-chain risks could impair earnings?

Key risks are supply and quality, not litigation.

Main risk categories

• Container supplier disruptions or raw material shortages
• Extractables/leachables issues discovered during stability updates or post-market surveillance
• Sterility assurance failures, recalls, or extended hold times
• Regulatory changes that require supplemental stability or CMC updates

How investors should model impact

• Earnings sensitivity to lost weeks of supply
• Working capital impact from inventory build cycles
• Cash burn from remediation and revalidation after deviations

What patent litigation affects dextrose 7.7% products?

For dextrose commodity solutions, patent litigation is typically limited and not the primary driver of business outcomes. When litigation occurs, it is usually narrow to:

• specific formulation or container system claims
• process validation claims
• secondary patents tied to manufacturing steps

Practical monitoring focus

• Any Orange Book listing tied to the specific presentation and concentration
• Court dockets for the named NDA/ANDA holder entities for “sterile solution” related disputes

Is there a licensing or settlement pathway that can create value?

Licensing value is usually constrained because competitors can often enter with alternatives at the product category level. Any settlement or license that restrains entry would generally need:

• enforceable patents that map tightly to the approved generic’s planned product
• a history of Paragraph IV or similar challenges tied to listed patents

In most cases, settlements are not large and durable value creation engines for commodity IV solutions.

Commercial metrics investors should use for dextrose 7.7%

Use metrics that connect operational execution to revenue and margin.

Core KPIs

• Net sales trend vs tender cycles
• Gross margin vs freight and container costs
• Share of supply by hospital group or distributor channel
• Rate of supply disruptions (fills delayed, backorders, recalls)
• Claims and chargebacks linked to distribution performance

Margin drivers

• Bulk dextrose input pricing
• Container cost and qualification requirements
• Labor and overhead per batch
• Yield and reprocessing rates in sterile fill-finish

Scenario analysis: base, downside, and upside drivers

Because the category is commoditized, three scenarios should be framed around pricing and supply reliability.

Base case

• Modest price compression in line with tender-driven competition
• Stable supply with no material quality events
• Margin supported by scale and stable input costs

Downside case

• Accelerated tender repricing due to new multi-source supply
• One or more supply disruptions from sterility deviation, inspection findings, or container constraints
• Margin compression from unfavorable input costs or forced expediting

Upside case

• Gaining or defending share through reliable supply and competitive net pricing
• Cost advantage from lower input or improved batch yields
• Expanded portfolio share across dextrose concentrations or bag sizes

Key Takeaways

• Dextrose 7.7% in plastic container is a commoditized sterile IV solution where operational excellence and supply continuity drive outcomes more than patent exclusivity.
• Patent estates, where present, are usually not a durable moat at the category level; investment risk skews toward price compression and CMC/manufacturing execution.
• The main drivers to underwrite are net pricing vs multi-source competition, input and container cost volatility, FDA/quality record, and the ability to maintain uninterrupted hospital supply through tender cycles.

FAQs

1. Does dextrose 7.7% have meaningful exclusivity under Hatch-Waxman-style frameworks?
   Typically not; market entry is usually limited by CMC readiness and inspection outcomes rather than long exclusivity.

2. Which cost items most influence gross margin for dextrose IV solutions?
   Pharmaceutical-grade dextrose input, container/closure costs, sterile fill-finish overhead, freight, and yield.

3. How do tender cycles at hospitals affect revenue predictability for dextrose 7.7%?
   Revenue is volatile when contracts reset; share gains and losses often track pricing and delivery reliability more than brand factors.

4. What quality events are most financially damaging for sterile IV injectables?
   Sterility assurance failures, recalls, extended batch holds, and repeated deviations that trigger revalidation or inspection escalations.

5. Are biosimilars relevant to dextrose 7.7% investment cases?
   No; this is a small-molecule IV infusion, not a biologic.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. FDA. Applications for FDA Approval to Market New Drugs and Changes to an Approved Application. (Industry guidance documents and regulatory framework).
3. USP. General Chapters for IV solutions and quality/compendial requirements applicable to dextrose solutions.